Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Novacyt ( (FR:ALNOV) ) is now available.
Novacyt S.A. has announced its monthly update regarding its liquidity agreement with Invest Securities SA, detailing the trading of ordinary shares between 1 April and 30 April 2025. During this period, Invest Securities purchased and sold shares at varying prices, with the total number of shares held in treasury being 92,902. The total number of ordinary shares in the company stands at 70,626,248, which is relevant for shareholder interest notifications. This update reflects Novacyt’s ongoing efforts to manage its share liquidity and maintain transparency with its stakeholders.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services, primarily focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation to deliver solutions across sectors such as human health, animal health, and environmental. Novacyt operates in three segments: Clinical, Instrumentation, and Research Use Only, and is headquartered in France with a commercial presence in over 65 countries.
YTD Price Performance: -15.65%
Average Trading Volume: 150
Technical Sentiment Signal: Buy
Current Market Cap: $36.95M
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.